Cytori Cell Research Institute, Inc. (3750.T)
JPY 671.0
(-0.74%)
JPY 671.0
(-0.74%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 1.43 Billion JPY | -80.59% |
| 2022 | 7.38 Billion JPY | -12.27% |
| 2021 | 8.41 Billion JPY | 12.77% |
| 2020 | 7.46 Billion JPY | -3.89% |
| 2019 | 7.76 Billion JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 1.78 Billion JPY | 24.66% |
| 2023 Q3 | 7.04 Billion JPY | -9.14% |
| 2023 FY | 1.43 Billion JPY | -80.59% |
| 2023 Q4 | 1.43 Billion JPY | -79.65% |
| 2023 Q2 | 7.75 Billion JPY | 3.08% |
| 2023 Q1 | 7.52 Billion JPY | 1.88% |
| 2022 Q3 | 7.32 Billion JPY | -3.5% |
| 2022 Q2 | 7.58 Billion JPY | 0.0% |
| 2022 Q4 | 7.38 Billion JPY | 0.87% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 742.75 Million JPY | -93.002% |
| PRISM BioLab Co.,LTD | -1.13 Billion JPY | 226.421% |
| GNI Group Ltd. | -17.93 Billion JPY | 107.994% |
| Linical Co., Ltd. | -4.46 Billion JPY | 132.118% |
| Trans Genic Inc. | -221.16 Million JPY | 748.164% |
| MEDINET Co., Ltd. | -4.39 Billion JPY | 132.625% |
| Soiken Holdings Inc. | -4.79 Billion JPY | 129.928% |
| AnGes, Inc. | -3.79 Billion JPY | 137.747% |
| OncoTherapy Science, Inc. | -420.8 Million JPY | 440.664% |
| Nxera Pharma Co., Ltd. | 24.9 Billion JPY | 94.245% |
| Immuno-Biological Laboratories Co., Ltd. | -498.15 Million JPY | 387.77% |
| NanoCarrier Co., Ltd. | -466.34 Million JPY | 407.397% |
| Carna Biosciences, Inc. | -2.7 Billion JPY | 152.974% |
| CanBas Co., Ltd. | -1.88 Billion JPY | 175.921% |
| D. Western Therapeutics Institute, Inc. | -982.14 Million JPY | 245.96% |
| RaQualia Pharma Inc. | -3.39 Billion JPY | 142.2% |
| Chiome Bioscience Inc. | -1.03 Billion JPY | 238.566% |
| Kidswell Bio Corporation | 343.58 Million JPY | -317.224% |
| PeptiDream Inc. | 3.29 Billion JPY | 56.454% |
| Oncolys BioPharma Inc. | -972.59 Million JPY | 247.393% |
| Ribomic Inc. | -2.09 Billion JPY | 168.272% |
| SanBio Company Limited | -3.78 Billion JPY | 137.827% |
| Healios K.K. | -2.19 Billion JPY | 165.458% |
| BrightPath Biotherapeutics Co., Ltd. | -944.85 Million JPY | 251.72% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -2.62 Billion JPY | 154.629% |
| Delta-Fly Pharma, Inc. | -1.41 Billion JPY | 201.163% |
| StemRIM | -8.41 Billion JPY | 117.046% |
| CellSource Co., Ltd. | -4.68 Billion JPY | 130.608% |
| FunPep Company Limited | -1.79 Billion JPY | 179.935% |
| Kringle Pharma, Inc. | -2.13 Billion JPY | 167.098% |
| Stella Pharma Corporation | -1.11 Billion JPY | 228.063% |
| TMS Co., Ltd. | -3.44 Billion JPY | 141.592% |
| Noile-Immune Biotech Inc. | -5.55 Billion JPY | 125.803% |
| Cuorips Inc. | -5.56 Billion JPY | 125.778% |
| K Pharma,Inc. | -3.26 Billion JPY | 143.887% |
| Takara Bio Inc. | -32.2 Billion JPY | 104.452% |
| ReproCELL Incorporated | -2.93 Billion JPY | 148.775% |
| PhoenixBio Co., Ltd. | -660.96 Million JPY | 316.887% |
| StemCell Institute Inc. | -2.83 Billion JPY | 150.534% |
| Japan Tissue Engineering Co., Ltd. | -2.06 Billion JPY | 169.376% |
| CellSeed Inc. | -2.01 Billion JPY | 171.248% |